Anaptysbio (ANAB) Return on Equity (2017 - 2026)

Anaptysbio (ANAB) has 10 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity rose 2.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 2.0% YoY), and the FY2025 full-year result was 0.0%, up 2.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, down from 0.0% in the prior quarter.
• Across five years, Return on Equity topped out at 0.25% in Q2 2025 and bottomed at 0.03% in Q1 2025.
• The 5-year median for Return on Equity is 0.0% (2022), against an average of 0.01%.
• Peak annual rise in Return on Equity reached 25 bps in 2025, while the deepest fall reached 3 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then surged by 110 bps to 0.0% in 2023, then sank by 4639 bps to 0.02% in 2024, then jumped by 98 bps to 0.0% in 2025, then slumped by 1205 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.

Peer Comparison